Skip to main content

Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis.

Publication ,  Journal Article
Nahid, P; Bliven, EE; Kim, EY; Mac Kenzie, WR; Stout, JE; Diem, L; Johnson, JL; Gagneux, S; Hopewell, PC; Kato-Maeda, M ...
Published in: PLoS One
May 20, 2010

Recent studies suggest that M. tuberculosis lineage and host genetics interact to impact how active tuberculosis presents clinically. We determined the phylogenetic lineages of M. tuberculosis isolates from participants enrolled in the Tuberculosis Trials Consortium Study 28, conducted in Brazil, Canada, South Africa, Spain, Uganda and the United States, and secondarily explored the relationship between lineage, clinical presentation and response to treatment. Large sequence polymorphisms and single nucleotide polymorphisms were analyzed to determine lineage and sublineage of isolates. Of 306 isolates genotyped, 246 (80.4%) belonged to the Euro-American lineage, with sublineage 724 predominating at African sites (99/192, 51.5%), and the Euro-American strains other than 724 predominating at non-African sites (89/114, 78.1%). Uneven distribution of lineages across regions limited our ability to discern significant associations, nonetheless, in univariate analyses, Euro-American sublineage 724 was associated with more severe disease at baseline, and along with the East Asian lineage was associated with lower bacteriologic conversion after 8 weeks of treatment. Disease presentation and response to drug treatment varied by lineage, but these associations were no longer statistically significant after adjustment for other variables associated with week-8 culture status.

Duke Scholars

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

May 20, 2010

Volume

5

Issue

5

Start / End Page

e10753

Location

United States

Related Subject Headings

  • Tuberculosis, Pulmonary
  • Risk Factors
  • Randomized Controlled Trials as Topic
  • Phylogeny
  • Mycobacterium tuberculosis
  • Humans
  • General Science & Technology
  • Algorithms
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nahid, P., Bliven, E. E., Kim, E. Y., Mac Kenzie, W. R., Stout, J. E., Diem, L., … Tuberculosis Trials Consortium. (2010). Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. PLoS One, 5(5), e10753. https://doi.org/10.1371/journal.pone.0010753
Nahid, Payam, Erin E. Bliven, Elizabeth Y. Kim, William R. Mac Kenzie, Jason E. Stout, Lois Diem, John L. Johnson, et al. “Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis.PLoS One 5, no. 5 (May 20, 2010): e10753. https://doi.org/10.1371/journal.pone.0010753.
Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, et al. Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. PLoS One. 2010 May 20;5(5):e10753.
Nahid, Payam, et al. “Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis.PLoS One, vol. 5, no. 5, May 2010, p. e10753. Pubmed, doi:10.1371/journal.pone.0010753.
Nahid P, Bliven EE, Kim EY, Mac Kenzie WR, Stout JE, Diem L, Johnson JL, Gagneux S, Hopewell PC, Kato-Maeda M, Tuberculosis Trials Consortium. Influence of M. tuberculosis lineage variability within a clinical trial for pulmonary tuberculosis. PLoS One. 2010 May 20;5(5):e10753.

Published In

PLoS One

DOI

EISSN

1932-6203

Publication Date

May 20, 2010

Volume

5

Issue

5

Start / End Page

e10753

Location

United States

Related Subject Headings

  • Tuberculosis, Pulmonary
  • Risk Factors
  • Randomized Controlled Trials as Topic
  • Phylogeny
  • Mycobacterium tuberculosis
  • Humans
  • General Science & Technology
  • Algorithms